ReviewImmunoTargets and therapy2021
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches.
Review in ImmunoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 56 citations in OpenAlex.
- Do Diet, Oral Hygiene, and Sleep Habits Correlate with Severe COVID-19?International journal of preventive medicine · 2026Article
- Serological profile of naïve patients affected by the first sars-cov-2 variant: A prospective study.PloS one · 2026Article
- Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.PloS one · 2026Article
- In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants.Scientific reports · 2024Article
- Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance.BMC infectious diseases · 2024Article
- Analysis of peripheral lymphocyte subsets and T-cell exhaustion in SARS-CoV-2 Infection.Tuberkuloz ve toraks · 2024Article
- Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID.Inflammopharmacology · 2023Review
- Changes in Adenosine Deaminase Activity and Endothelial Dysfunction after Mild Coronavirus Disease-2019.International journal of molecular sciences · 2023Article
- Trends in the Epidemiology ofJournal of fungi (Basel, Switzerland) · 2023Review
- T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- Rationale for combined therapies in severe-to-critical COVID-19 patients.Frontiers in immunology · 2023Review
- Simulation of COVID-19 symptoms in a genetically engineered mouse model: implications for the long haulers.Molecular and cellular biochemistry · 2023Article
- Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts.Dialogues in health · 2022Article
- The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.Journal of medical virology · 2022Review
- Article
- Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy.Biochimica et biophysica acta. Molecular basis of disease · 2022Article
- COVID-19 vaccine associated cervical lymphadenopathy: a case series.ANZ journal of surgery · 2022Article
- Review
- RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from asymptomatic to severe/critical disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 to infect cells leading to a strong inflammatory response, which is most profound in patients who progress to severe Covid-19. Recent studies have begun to unravel some of the differences in the innate and adaptive immune response to SARS-CoV-2 in patients with different degrees of disease severity. These studies have attributed the severe form of Covid-19 to a dysfunctional innate immune response, such as a delayed and/or deficient type I interferon response, coupled with an exaggerated and/or a dysfunctional adaptive immunity. Differences in T-cell (including CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.